ArticleScientific reports2026
Acute anterior segment biometric effects of brimonidine assessed by swept source OCT supporting its use in managing visual disturbances.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study quantified the effects of topical brimonidine 0.2% on anterior segment anatomy using swept-source optical coherence tomography (SS-OCT) in a prospective, interventional design. Seventy eyes were evaluated with the Anterion system. Baseline measurements were taken, followed by the instillation of one drop of brimonidine tartrate 0.2%. A second scan was performed 60 min later. Key outcomes included pupillary diameter (PD), angle opening distance at 500 μm (AOD500), iris thickness (IT), anterior chamber depth (ACD), lens vault (LV), lens thickness (LT), and white-to-white distance (WTW). Results showed a statistically significant reduction in PD and an increase in AOD500 and ACD after brimonidine, while IT decreased. No significant changes occurred in LV, LT, or WTW. Baseline gender differences were noted, with females exhibiting a larger PD and smaller AOD500 and ACD than males, as previously reported. The study also contributes normative biometric data for a Hispanic population, highlighting these relevant anatomical variations. Results show that brimonidine induces significant miosis and angle widening without altering lens parameters, supporting its potential use in managing postoperative photic phenomena. This study provides objective SS-OCT quantification of brimonidine's multiple acute effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.